Smooth Muscle Myosin Heavy Chain (SM-MHC) (Leiomyosarcoma & Myoepithelial Cell Marker) Antibody
Mouse Monoclonal Antibody [Clone MYH11/923 + SMMS-1 ]
|Application ||IHC, IF, FC|
|Other Accession||4629, 460109|
|Isotype||Mouse / IgG's|
|Clone Names||MYH11/923 + SMMS-1|
|Calculated MW||205kDa (MHC-1) and 200kDa (MHC-2)|
|Other Names||Myosin-11, Myosin heavy chain 11, Myosin heavy chain, smooth muscle isoform, SMMHC, MYH11, KIAA0866|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Smooth Muscle Myosin Heavy Chain (SM-MHC) (Leiomyosarcoma & Myoepithelial Cell Marker) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Thick filaments of the myofibrils|
|Tissue Location||Smooth muscle; expressed in the umbilical artery, bladder, esophagus and trachea. Isoform 1 is mostly found in slowly contracting tonic muscles|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Smooth muscle myosin heavy chain (SM-MHC) is a cytoplasmic structural protein, which is a major component of the contractile apparatus in smooth muscle cells. Expression of smooth muscle myosin is developmentally regulated, appearing early in smooth muscle development, and is specific for smooth muscle development. Two isoforms of smooth muscle myosin heavy chain have been identified, designated MHC-1 and MHC-2. The antibody may be useful for the study of breast tumors as the presence of an intact layer of myoepithelial cells is an important feature, which may distinguish benign breast lesions and carcinoma in situ from invasive tumors.
N.P. Wang, B.C. Wan, M. Skelly, M.G. Frid, M.A. Glukhova, V.E. Koteliansky, A.M. Gown. Antibodies to novel myoepithelium-associated proteins distinguish benign lesions and in-situ- carcinoma from invasive carcinoma of the breast. Applied Immunohistochemistry 1997;5(3):141-151
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.